Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Hypertonic saline with quinine sulphate for cystic fibrosis hospital admissions
ACTRN12605000780651Phase 3Withdrawn
- Sponsor
- Sydney South West Area Health Service
- Start
- Dec 2005
- Modality
- Small Molecules, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3 trial of hypertonic saline and quinine in cystic fibrosis (CF) (2 arms), sponsored by Sydney South West Area Health Service. Primary endpoint: Duration of hospital length of stay. Planned start Dec 2005; status: withdrawn.
02
Drugs
hypertonic salinequinine
03
Conditions
cystic fibrosis (CF)
Beyond the preview
Go deeper on ACTRN12605000780651.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12605000780651.